{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:23:32Z","timestamp":1787163812195,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,30]],"date-time":"2018-05-30T00:00:00Z","timestamp":1527638400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Takeda Pharmaceutical International, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13075-018-1593-0","type":"journal-article","created":{"date-parts":[[2018,5,30]],"date-time":"2018-05-30T08:32:37Z","timestamp":1527669157000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2232-8931","authenticated-orcid":false,"given":"Lhanoo","family":"Gunawardhana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Whelton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majin","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Saag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,30]]},"reference":[{"key":"1593_CR1","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64:1431\u201346.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1593_CR2","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.amjmed.2011.09.033","volume":"125","author":"Y Zhu","year":"2012","unstructured":"Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med. 2012;125:679\u201387.","journal-title":"Am J Med"},{"key":"1593_CR3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1471-2369-12-36","volume":"12","author":"MJ Fuldeore","year":"2011","unstructured":"Fuldeore MJ, Riedel AA, Zarotsky V, Pandya BJ, Dabbous O, Krishnan E. Chronic kidney disease in gout in a managed care setting. BMC Nephrol. 2011;12:36.","journal-title":"BMC Nephrol"},{"key":"1593_CR4","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1093\/ndt\/gft029","volume":"28","author":"RJ Johnson","year":"2013","unstructured":"Johnson RJ, Nakagawa T, Jalal D, Sanchez-Lozada LG, Kang DH, Ritz E. Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transplant. 2013;28:2221\u20138.","journal-title":"Nephrol Dial Transplant"},{"key":"1593_CR5","doi-asserted-by":"publisher","first-page":"e50046","DOI":"10.1371\/journal.pone.0050046","volume":"7","author":"E Krishnan","year":"2012","unstructured":"Krishnan E. Reduced glomerular function and prevalence of gout: NHANES 2009-10. PLoS One. 2012;7:e50046.","journal-title":"PLoS One"},{"key":"1593_CR6","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13075-015-0610-9","volume":"17","author":"MJ Roughley","year":"2015","unstructured":"Roughley MJ, Belcher J, Mallen CD, Roddy E. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies. Arthritis Res Ther. 2015;17:90.","journal-title":"Arthritis Res Ther"},{"key":"1593_CR7","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1002\/art.39654","volume":"68","author":"KG Saag","year":"2016","unstructured":"Saag KG, Whelton A, Becker MA, MacDonald P, Hunt B, Gunawardhana L. Impact of febuxostat on renal function in gout patients with moderate-to-severe renal impairment. Arthritis Rheumatol. 2016;68:2035\u201343.","journal-title":"Arthritis Rheumatol"},{"key":"1593_CR8","unstructured":"AA Pharma Inc. ZYLOPRIM\u00ae: Allopurinol tablets USP; 100, 200 and 300 mg (product mongraph). \n                    https:\/\/www.aapharma.ca\/downloads\/en\/PIL\/allopurinol_pm.pdf\n                    \n                  . Accessed 10 Apr 2017."},{"key":"1593_CR9","doi-asserted-by":"crossref","unstructured":"Stamp LK, Chapman PT, Barclay ML, Horne A, Frampton C, Tan P, et al. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Ann Rheum Dis. 2017;76:1522\u201328","DOI":"10.1136\/annrheumdis-2016-210872"},{"key":"1593_CR10","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1002\/art.20935","volume":"52","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR Jr, Wortmann RL, Macdonald PA, Palo WA, Eustace D, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 2005;52:916\u201323.","journal-title":"Arthritis Rheum"},{"key":"1593_CR11","unstructured":"Takeda Pharmaceuticals America Inc. ULORIC (febuxostat) tablets: prescribing information. \n                    http:\/\/general.takedapharm.com\/content\/file.aspx?filetypecode=ULORICPI&cacheRandomizer=a9b8bc72-9cd9-42de-834a-d3d2ea6ef737\n                    \n                  . Accessed 10 Apr 2017."},{"key":"1593_CR12","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR Jr, Wortmann RL, Macdonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353:2450\u201361.","journal-title":"N Engl J Med"},{"key":"1593_CR13","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.3899\/jrheum.080814","volume":"36","author":"MA Becker","year":"2009","unstructured":"Becker MA, Schumacher HR, Macdonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009;36:1273\u201382.","journal-title":"J Rheumatol"},{"key":"1593_CR14","doi-asserted-by":"publisher","first-page":"R63","DOI":"10.1186\/ar2978","volume":"12","author":"MA Becker","year":"2010","unstructured":"Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12:R63.","journal-title":"Arthritis Res Ther"},{"key":"1593_CR15","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/art.24209","volume":"59","author":"HR Schumacher Jr","year":"2008","unstructured":"Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59:1540\u20138.","journal-title":"Arthritis Rheum"},{"key":"1593_CR16","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/rheumatology\/ken457","volume":"48","author":"HR Schumacher Jr","year":"2009","unstructured":"Schumacher HR Jr, Becker MA, Lloyd E, Macdonald PA, Lademacher C. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009;48:188\u201394.","journal-title":"Rheumatology (Oxford)"},{"key":"1593_CR17","unstructured":"Takeda Pharmaceuticals America Inc. Febuxostat: Study No. TMX-67_106; Clinical Study Report (synopsis). \n                    https:\/\/www.takedaclinicaltrials.com\/files2\/TMX-67-106-RDS-2014-10-26.pdf\n                    \n                  . Accessed 10 Apr 2017."},{"key":"1593_CR18","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/art.1780200320","volume":"20","author":"SL Wallace","year":"1977","unstructured":"Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977;20:895\u2013900.","journal-title":"Arthritis Rheum"},{"key":"1593_CR19","unstructured":"Saag K, Becker MA, Whelton A, Hunt B, Castillo M, Kisfalvi K, et al. A phase 3 study to evaluate the efficacy and safety of febuxostat extended- versus immediate-release formulations in patients with gout. Arthritis Rheumatol. 2016;68(Suppl 10):Abstract 199."},{"key":"1593_CR20","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3810\/pgm.2013.01.2626","volume":"125","author":"A Whelton","year":"2013","unstructured":"Whelton A, Macdonald PA, Chefo S, Gunawardhana L. Preservation of renal function during gout treatment with febuxostat: a quantitative study. Postgrad Med. 2013;125:106\u201314.","journal-title":"Postgrad Med"},{"key":"1593_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/RHU.0b013e318204aab4","volume":"17","author":"A Whelton","year":"2011","unstructured":"Whelton A, Macdonald PA, Zhao L, Hunt B, Gunawardhana L. Renal function in gout: long-term treatment effects of febuxostat. J Clin Rheumatol. 2011;17:7\u201313.","journal-title":"J Clin Rheumatol"},{"key":"1593_CR22","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1053\/j.ajkd.2015.05.017","volume":"66","author":"D Sircar","year":"2015","unstructured":"Sircar D, Chatterjee S, Waikhom R, Golay V, Raychaudhury A, Chatterjee S, et al. Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-month, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis. 2015;66:945\u201350.","journal-title":"Am J Kidney Dis"},{"key":"1593_CR23","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/hdi.12313","volume":"19","author":"Y Tsuruta","year":"2015","unstructured":"Tsuruta Y, Kikuchi K, Tsuruta Y, Sasaki Y, Moriyama T, Itabashi M, et al. Febuxostat improves endothelial function in hemodialysis patients with hyperuricemia: a randomized controlled study. Hemodial Int. 2015;19:514\u201320.","journal-title":"Hemodial Int"},{"key":"1593_CR24","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1007\/s10157-015-1095-1","volume":"19","author":"K Tanaka","year":"2015","unstructured":"Tanaka K, Nakayama M, Kanno M, Kimura H, Watanabe K, Tani Y, et al. Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial. Clin Exp Nephrol. 2015;19:1044\u201353.","journal-title":"Clin Exp Nephrol"},{"key":"1593_CR25","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1097\/JTO.0b013e3181e2eadf","volume":"5","author":"SJ Mandrekar","year":"2010","unstructured":"Mandrekar SJ, Sargent DJ. Randomized phase II trials: time for a new era in clinical trial design. J Thorac Oncol. 2010;5:932\u20134.","journal-title":"J Thorac Oncol"},{"key":"1593_CR26","doi-asserted-by":"crossref","unstructured":"Tomblyn MR, Rizzo JD. Are there circumstances in which phase 2 study results should be practice-changing? Hematology Am Soc Hematol Educ Program. 2007:489\u201392.","DOI":"10.1182\/asheducation-2007.1.489"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1593-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-018-1593-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1593-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T19:10:52Z","timestamp":1559157052000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-018-1593-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,30]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1593"],"URL":"https:\/\/doi.org\/10.1186\/s13075-018-1593-0","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,30]]},"assertion":[{"value":"14 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Each investigator conducted the study according to the Declaration of Helsinki and the International Conference on Harmonisation\u2019s Harmonised Tripartite Guideline for good clinical practices, and in compliance with applicable local or regional regulatory requirements. All patients enrolled in the study provided written informed consent in the manner deemed appropriate by the institutional review board or the independent ethics committees. For the full list of review boards and ethics committees providing approval, please see Additional\u00a0file\u00a0\n                      \n                      .","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"LG is an employee of and owns stocks\/stock options in Takeda Pharmaceuticals USA, Inc. MAB has received research grants from Ardea\/AstraZeneca, Horizon, and Takeda and consultancy\/other remuneration from Ardea\/AstraZeneca, CymaBay, Horizon, Ironwood, and Takeda (total remuneration: Ardea\/AstraZeneca, >\u2009$10,000; CymaBay, <\u2009$10,000; Horizon, <\u2009$10,000; Ironwood, <\u2009$10,000; and Takeda, >\u2009$10,000). AW is a consultant for Takeda (<\u2009$10,000). BH and MC are employees of Takeda Pharmaceuticals USA, Inc. KS has received research grants from Ardea\/AstraZeneca, Horizon, SOBI and Takeda (>\u2009$10,000 from each company) and consultancy\/other remuneration from Ardea\/AstraZeneca (>\u2009$10,000), Horizon, Ironwood, SOBI, and Takeda (<\u2009$10,000 from each company).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"99"}}